Results 341 to 350 of about 9,561,546 (382)
Some of the next articles are maybe not open access.
Neurologic Clinics, 2001
A number of changes have occurred in the management of Parkinson's disease in recent years, with the development of new therapeutic strategies based upon advances in pharmacotherapy and interventional procedures. The treatment of patients with Parkinson's disease is considered here with these advances in mind.
A E, Constantino, L S, Honig
openaire +5 more sources
A number of changes have occurred in the management of Parkinson's disease in recent years, with the development of new therapeutic strategies based upon advances in pharmacotherapy and interventional procedures. The treatment of patients with Parkinson's disease is considered here with these advances in mind.
A E, Constantino, L S, Honig
openaire +5 more sources
Parkinson's Disease and Parkinsonism
The American Journal of Medicine, 2019Parkinson's disease is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. Male sex and advancing age are independent risk factors and, as the population ages, is taking an increasing toll on productivity and medical resources.
openaire +2 more sources
Genetics of Parkinson’s disease and parkinsonism
Expert Review of Neurotherapeutics, 2007The past 10 years has seen a shift in our etiological concepts of Parkinson's disease, moving from a nearly exclusively environmentally mediated disease towards a complex disorder with important genetic contributors. The identification of responsible mutations in certain genes, particularly alpha-synuclein, Parkin, PINK1, DJ-1 and LRRK2, has increased ...
David J Nicholl +2 more
openaire +3 more sources
Clinical evidence, 2002
Around 1% of adults have Parkinson's disease, with a median time of 9 years between diagnosis and death.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments in people with early-stage Parkinson's disease?
Carl E, Clarke, A Peter, Moore
openaire +7 more sources
Around 1% of adults have Parkinson's disease, with a median time of 9 years between diagnosis and death.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments in people with early-stage Parkinson's disease?
Carl E, Clarke, A Peter, Moore
openaire +7 more sources
Genetics of Parkinson's disease and parkinsonism
Annals of Neurology, 2006AbstractUntil 10 years ago, conventional wisdom held that Parkinson's disease was not a genetic disorder. Since that time, there have been a plethora of genetic findings, culminating in the cloning of several genes that derive from the loci given the nomenclature PARK1‐PARK12 (OMIM 168600).
Andrew B. Singleton +4 more
openaire +3 more sources
The Lancet, 2015
Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long been characterised by the classical motor features of parkinsonism associated with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, the symptomatology of Parkinson's disease is now recognised as heterogeneous, with clinically ...
L. Kalia, A. Lang
semanticscholar +3 more sources
Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long been characterised by the classical motor features of parkinsonism associated with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, the symptomatology of Parkinson's disease is now recognised as heterogeneous, with clinically ...
L. Kalia, A. Lang
semanticscholar +3 more sources
Identification of parkinsonism and Parkinson's disease
Drugs of Today, 2002Parkinson's disease is a common movement disorder associated with considerable disability. The clinical syndrome of parkinsonism is based on the presence of core clinical features of rest tremor, bradykinesia, rigidity and impaired postural reflexes or gait.
openaire +3 more sources